Calls for papers
-
Arikayce inhaled amikacin deveoper Insmed Incorporated has announced the appointments of Paolo Tombesi as Chief Financial Officer, Paul Streck as Chief Medical Officer, and Eugene Sullivan as Chief Product Strategy Officer. Tombesi was most recently… Read more . . .
-
Milestone Pharmaceuticals has announced positive results from the Phase 2 NODE-1 study of intranasal etripamil for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT), a type of cardiac arrhythmia. The double-blind dose ranging study… Read more . . .
-
Inhalation Asia 2017, which will take place September 13-15, has announced a change of venue from Hong Kong to Macau. The meeting will now take place on the campus of the University of Macau. Dr.… Read more . . .
-
According to Vectura, its partner Hikma Pharmaceuticals has received a complete response letter from the FDA to its ANDA for VR315 fluticasone propionate/salmeterol DPI, a generic version of GSK’s Advair Diskus. Vectura said that the… Read more . . .
-
The IMPALA Phase 2/3 trial for Savara’s Molgradex inhaled molgramostim for the treatment of autoimmune pulmonary alveolar proteinosis (PAP) will be modified in order to qualify as a pivotal study for a US regulatory submission,… Read more . . .
-
Pharmaxis has announced that Chiesi Farmaceutici will take over marketing and distribution of Bronchitol mannitol DPI in Italy. Bronchitol has been approved in the EU for the treatment of cystic fibrosis in patients 18 years… Read more . . .
-
Dalton Pharma Services will take responsibility for GMP preparation and filling into glass vials of Arch Biopartners’ AB569 bactericidal inhalation solution for an upcoming Phase 1 trial, the companies have announced. Dalton will provide a… Read more . . .
-
Pulmatrix has announced the receipt of US patent No. 9,642,798, titled “Monovalent metal cation dry powders for inhalation,” which covers its PUR0200 dry powder formulation of tiotropium bromide for the treatment of COPD. In July… Read more . . .
-
According to intranasal drug developer OptiNose, the company has raised $37 million in a Series D financing round led by Fidelity Management and Research Company. The company said that it plans to use the money… Read more . . .
-
Innovus Pharmaceuticals will launch a fluticasone propionate nasal spray under the brand name FlutiCare in the US by the end of 2017 after acquiring rights to the product from West-Ward Pharmaceuticals International Limited (WWPIL). The… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK